Vector BioMed, Inc.

Headed to New Orleans for #ASGCT2025? Find us at Booth # 1348 during the American Society of Gene & Cell Therapy Annual Meeting, May 13 - 17. Whether you're working on early-stage development or looking to scale your CGT program, Vector BioMed is here to help you move faster, drive costs down, and gain real-time access to custom and standard platform solutions. Let's talk: - Smarter lentiviral vector (LV) design and development - Fast, scalable, and cost-effective GMP LV production - How we're supporting global partners from concept to clinic 👋 Stop by to meet: Shashi Koduru, Senior Director, Business Development Bryce Goodman, Director, Marketing and Communications We’d love to hear what you’re working on and how we can support it. Stop by Booth # 1348 and let’s start or continue the conversation.

We’re honored to be featured in the Global Showcase Theatre at #ISCT2025, joining a remarkable lineup of CGT leaders. As part of the Global Showcase, Dr. Boro Dropulić will share insights on ‘The Next Frontier in Lentiviral Manufacturing,’ exploring a pivotal mindset and necessary approaches to redefine what’s possible in CGT.

Excited to share that our Executive Director, Dr. Boro Dropulić, will be speaking at Abu Dhabi Global Healthcare Week on April 15 at 11:45 AM (GMT+4)! He’ll be joining Dr. Ajlan Al Zaki on a powerful panel: “Revolutionizing Cancer Care: Localizing CAR-T Therapy for Global Impact.” If you're attending, come see us at Booth A030 — we'd love to connect! #BurjeelHoldings #ADGHW #LeadingTheShift #PoweringTheBreakthroughs #CARTtherapy #GlobalHealthEquity #ADGHW2025

We’re headed to New Orleans next month for #ISCT2025! 🗓️ May 7–10, 2025 📍 Booth # 937 At a time when cost, complexities, and delays continue to pose significant challenges to gene therapy development, Vector BioMed brings a true vector solution to ISCT - of low cost, expert vector design, and turnkey processes. Working with CDMOs should be low friction, simple, and a value add - getting affordable materials in your hands in the shortest amount of time possible. ‘Next Generation’ therapeutics require next generation service providers - with the right knowledge to make an impact. Catch Dr. Boro Dropulić during his Global Showcase Presentation, where he’ll explore ‘The Next Frontier in Lentiviral Manufacturing,’ which will identify steps required to transform the CGT landscape. Connect directly with our attendees: Dr. Boro Dropulić, Chief Executive Officer Kim Bure, Director of Sales Let’s meet to talk about the next chapter in lentiviral manufacturing: one that’s faster, smarter, and accessible from around the globe. ISCT, International Society for Cell & Gene Therapy #ISCT #CGT #GeneTherapy #CellTherapy

Biotech Educational Series: Next Seminar Alert! 💡 Innovative Payment Models in Cell & Gene Therapies One of the biggest challenges in advancing cell and gene therapies is the high cost of commercial products—leading to reimbursement issues and limiting patient access. But what if payment strategies based on health outcomes could change that? Join us next Friday as we dive into innovative payment models that could enhance drug distribution and improve access for patients in need. 📅 Date: April 4, 2025 ⏰ Time: 3:00pm EST 📍 Register Now: https://lnkd.in/ePwSKm8p Let’s shape the future of affordable and accessible cell & gene therapies together! 🔬🌍 #BiotechEducation #CellTherapy #GeneTherapy #HealthcareInnovation #PatientAccess

🌟 Exciting News from Brazil! 🌟 Our Executive Director, Dr. Boro Dropulić, recently presented and participated as a panelist at the IV International Seminar of IFA LATAM, ABIQUIFI, in São Paulo, Brazil! 🇧🇷 The event gathered experts, companies, and government leaders to discuss challenges and opportunities in the Active Pharmaceutical Ingredients (API) industry. 🔬 Dr. Dropulić shared insights on Caring Cross’ technology transfer collaboration with Bio-Manguinhos / Fiocruz, funded by the Ministry of Health of Brazil. Together, we’re advancing health equity by making life-saving therapies accessible where they’re needed most! #CaringCross #GlobalHealth #CAR_T #Fiocruz #Brazil #HealthcareInnovation #HealthEquity #APISeminar #CellTherapy #TechnologyTransfer

🗓️ Two events, one city, one team - Vector BioMed is looking forward to attending #ISCT2025 & #ASGCT2025 in New Orleans this May! Click or swipe right below for a preview of these groundbreaking industry events. Don't miss Dr. Boro Dropulić's Global Showcase Presentation at ISCT 2025, where he’ll discuss how premier lentiviral vector design and decentralized manufacturing are breaking down cost and access barriers in gene therapy. Details: https://lnkd.in/gBAEqupt Let’s connect in NOLA and together explore advanced and simplified viral vector manufacturing. With the right vision and specialized platform innovations, Vector BioMed, Inc. is making viral vectors truly accessible, providing a smarter path from concept to clinic - around the globe. Schedule a meeting with our team: 💻 Contact us: https://lnkd.in/eD4wbBES 📧 Email: partner@vectorbiomed.com Or connect directly with our attendees: Dr. Boro Dropulić, Chief Executive Officer Shashi Koduru, Senior Director, Business Development Kim Bure, Director of Sales Bryce Goodman, Director, Marketing and Communications ISCT, International Society for Cell & Gene Therapy / American Society of Gene & Cell Therapy #ISCT #ASGCT #CGT #AdvancedTherapies #cellandgenetherapy #lentiviralvector #NextGenTherapies #CARTcellTherapy #autologoustherapies #autologoustherapy #cellandgenetherapies

🚨 Exciting news! 🚨 Caring Cross is thrilled to announce a strategic collaboration with Koç Healthcare to bring affordable and accessible CAR-T cell therapies to patients in Türkiye! CAR-T cell therapy has revolutionized cancer treatment, but cost and accessibility remain major barriers—especially in regions reliant on overseas imports. Together, we are changing that. This partnership represents a major leap forward for health equity and innovation. We’re not just developing therapies—we’re building a sustainable model that makes world-class treatments available for all. Read the full announcement: https://lnkd.in/ePMwgvy7 #CAR_T #CellTherapy #GeneTherapy #HealthcareInnovation #HealthEquity #KoçHealthcare #CaringCross #Türkiye

🚀 Join Us at #HIMSS25 We’re excited to announce that Dr. Boro Dropulić, Executive Director of Caring Cross, will be presenting a compelling case study on health equity in action—showcasing how we are revolutionizing gene therapy accessibility through innovative, decentralized solutions. 📌 Session: Case Study – Health Equity in Action: Revolutionizing Gene Therapy Accessibility 📅 Date: Tuesday, March 4th ⏰ Time: 2:00–2:30 PM PST 📍 Location: Exhibit Hall | Connect Booth #3900 – SKY Theatre Dr. Dropulić will discuss how Caring Cross is addressing critical barriers in cell and gene therapy access, empowering healthcare systems worldwide to deliver cutting-edge treatments affordably and at the point of care. Hope you can join us at the HIMSS Global Health Conference & Exhibition to learn how innovative partnerships and technology transfer can transform the future of medicine! Want to learn more? Watch a panel discussion from last year’s #UNGA79 at the Devex Summit, where we explored how partnerships and innovation can drive health equity worldwide: https://lnkd.in/eAmDirdy #HealthEquity #GeneTherapy #CaringCross #FutureOfHealthcare

Lentiviral vector and improving the accessibility of CAR-T therapies, for all. Scan this short read to discover more about the global benefits of Vector BioMed, Inc.'s collaboration with Caring Cross. 👉 https://lnkd.in/eNNkr3q9 Today, we revisit this Fierce Pharma article from 2024 that highlights a global first... Building infrastructure and collaborations with years of expertise in your back pocket to accelerate the development of advanced medicines and make them available for all patients around the world. When you’re able to harness the power of a trailblazer for good, you’re able to shift the global industry’s view of logistics, cost, - and ultimately, standard of care. “Dropulić knows the drill. He founded Lentigen, which developed the lentiviral vector used by Novartis to produce the first FDA-approved cell therapy product, Kymriah, in 2017. Dropulic directed Lentigen’s CDMO business model before launching Caring Cross in 2021.” #CGT #AdvancedTherapies #cellandgenetherapy #lentiviralvector #NextGenTherapies #CARTcellTherapy #autologoustherapies #autologoustherapy #cellandgenetherapies